Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis

Jürgen Floege; David R W Jayne; Jan-Stephan F Sanders; Vladimír Tesar; Ethan M Balk; Craig E Gordon; Gaelen Adam; Marcello A Tonelli; Michael Cheung; Amy Earley; Brad H Rovin

doi:10.1016/j.kint.2023.10.009

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis

Jürgen Floege^*
, David R W Jayne
, Jan-Stephan F Sanders
, Vladimír Tesar
, Ethan M Balk
, Craig E Gordon
, Gaelen Adam
, Marcello A Tonelli
, Michael Cheung
, Amy Earley
, Brad H Rovin

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

162 Downloads (Pure)

Abstract

In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.

Original language	English
Pages (from-to)	447-449
Number of pages	3
Journal	Kidney International
Volume	105
Issue number	3
DOIs	https://doi.org/10.1016/j.kint.2023.10.009
Publication status	Published - Mar-2024

Keywords

Humans
Glomerulonephritis/diagnosis
Kidney
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis
Antibodies, Antineutrophil Cytoplasmic
Nephrology
Glucocorticoids/therapeutic use

Access to Document

10.1016/j.kint.2023.10.009Licence: CC BY-NC-ND

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA–Associated VasculitisFinal publisher's version, 164 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{7d55090340d24921af02b386e9340c32,

title = "Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis",

abstract = "In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.",

keywords = "Humans, Glomerulonephritis/diagnosis, Kidney, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis, Antibodies, Antineutrophil Cytoplasmic, Nephrology, Glucocorticoids/therapeutic use",

author = "J{\"u}rgen Floege and Jayne, \{David R W\} and Sanders, \{Jan-Stephan F\} and Vladim{\'i}r Tesar and Balk, \{Ethan M\} and Gordon, \{Craig E\} and Gaelen Adam and Tonelli, \{Marcello A\} and Michael Cheung and Amy Earley and Rovin, \{Brad H\}",

year = "2024",

month = mar,

doi = "10.1016/j.kint.2023.10.009",

language = "English",

volume = "105",

pages = "447--449",

journal = "Kidney International",

issn = "0085-2538",

publisher = "ELSEVIER SCIENCE INC",

number = "3",

}

TY - JOUR

T1 - Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis

AU - Floege, Jürgen

AU - Jayne, David R W

AU - Sanders, Jan-Stephan F

AU - Tesar, Vladimír

AU - Balk, Ethan M

AU - Gordon, Craig E

AU - Adam, Gaelen

AU - Tonelli, Marcello A

AU - Cheung, Michael

AU - Earley, Amy

AU - Rovin, Brad H

PY - 2024/3

Y1 - 2024/3

N2 - In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.

AB - In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.

KW - Humans

KW - Glomerulonephritis/diagnosis

KW - Kidney

KW - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis

KW - Antibodies, Antineutrophil Cytoplasmic

KW - Nephrology

KW - Glucocorticoids/therapeutic use

U2 - 10.1016/j.kint.2023.10.009

DO - 10.1016/j.kint.2023.10.009

M3 - Article

C2 - 38388147

SN - 0085-2538

VL - 105

SP - 447

EP - 449

JO - Kidney International

JF - Kidney International

IS - 3

ER -

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this